CJC-1295 vs Sermorelin: Dosing & GH Compared

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) with four amino acid substitutions that protect it from enzymatic degradation. It exists in two forms with dramatically different pharmacokinetics.

Sermorelin (sermorelin acetate) is a truncated form of natural GHRH, consisting of the first 29 amino acids of the 44-amino-acid endogenous hormone. These 29 amino acids contain the full biological activity needed to stimulate GH release from the pituitary.

Sermorelin was previously FDA-approved under the brand name Geref for the diagnosis and treatment of growth hormone deficiency in children (Prakash & Goa, BioDrugs, 1999). The manufacturer discontinued it due to manufacturing difficulties, not safety concerns. It is now available through compounding pharmacies with a prescription.

Its 10-20 minute half-life means each injection produces a single, sharp GH pulse that mirrors what your pituitary does naturally during deep sleep. Walker et al. confirmed that sermorelin preserves the pituitary's neuroendocrine axis and actually stimulates endogenous hGH mRNA production (Walker et al., 2006). Sermorelin does not just trigger GH release; it supports the pituitary's ability to make GH on its own.

For safety details, see is sermorelin safe. For body composition effects, see sermorelin for fat loss.

Think of GH secretion like a sprinkler system. Sermorelin is a quick burst from a garden hose: a sharp, powerful pulse that lasts seconds and then stops. CJC-1295 no-DAC is like a sprinkler on a 3-hour timer. CJC-1295 with DAC is a slow drip irrigation system that runs for a full week.

The literal numbers confirm this analogy.

Sermorelin's short half-life is both its limitation and its advantage. The limitation: you must inject daily. The advantage: each pulse closely replicates the body's natural GH secretion pattern. The pituitary gland normally releases GH in 6-12 bursts per day, with the largest pulse occurring during stage 3-4 sleep. Sermorelin injected before bed amplifies this natural nighttime surge without creating unnatural continuous elevation.

CJC-1295 with DAC eliminates the need for daily injections but creates continuous GHRH receptor stimulation. This may increase the risk of pituitary desensitization over time and produces more side effects related to sustained GH elevation (water retention, insulin resistance).

CJC-1295 wins on raw GH and IGF-1 output. The question is whether more is better for your specific goals.

CJC-1295 data (Teichman et al., 2006): In 21 healthy adults, a single dose of CJC-1295 with DAC at 30-60 mcg/kg produced 2-10-fold GH increases sustained for 6+ days. IGF-1 increased 1.5-3-fold and remained elevated for 9-11 days. After multiple weekly doses, mean IGF-1 levels stayed elevated for 28 days (PMID: 16352683).

Sermorelin data (Walker et al., 2006; Prakash & Goa, 1999): Sermorelin at 30 mcg/kg produced significant but shorter GH pulses. In pediatric studies, sermorelin increased growth velocity from 3.0 cm/year to 7.0 cm/year over 12 months, confirming clinically meaningful GH stimulation (PMID: 18031173). Adult studies show sermorelin preserves the pituitary neuroendocrine axis, meaning long-term GH production capacity is maintained (PMID: 18046908).

The tradeoff is clear. CJC-1295 produces higher, more sustained GH and IGF-1 levels. Sermorelin produces more physiologic pulses that preserve pituitary function. For short-term body composition goals, CJC-1295 may be more effective. For long-term GH axis health, sermorelin has the stronger argument.

Each compound requires a different injection schedule, reconstitution approach, and cycle structure.

Sermorelin's once-daily bedtime injection is the simplest protocol. The peptide amplifies your natural nighttime GH pulse and is cleared from your system by morning. No timing considerations for meals or exercise.

CJC-1295 no-DAC requires 2-3 daily injections for optimal results, which is the most demanding protocol. Most users pair each injection with ipamorelin and time doses around training and sleep.

CJC-1295 with DAC offers the most convenient schedule: one or two injections per week. The CJC-1295 dosage guide covers detailed protocols for each variant.

Both compounds are well-tolerated GHRH analogs. Neither elevates cortisol or prolactin, distinguishing them from GHRPs and other secretagogues. Side effects are GH-class effects (water retention, tingling, flushing) rather than compound-specific toxicities.

Sermorelin has the mildest side effect profile due to its short half-life and physiologic GH pulse pattern. CJC-1295 with DAC has the most pronounced side effects because sustained GH elevation drives more water retention and metabolic effects. For detailed side effect management, see our CJC-1295/ipamorelin side effects guide.

Peptide pricing varies by source, purity, and region. The following ranges represent compounded pharmacy pricing in the United States as of 2026.

All three options fall in a similar monthly range. The hidden cost difference lies in injection supplies. Sermorelin and CJC-1295 no-DAC require more insulin syringes per month (30-90 syringes) compared to CJC-1295 with DAC (4-8 syringes). Bacteriostatic water, alcohol swabs, and sharps disposal add $15-30/month regardless of the compound.

For sourcing, see where to buy sermorelin. Sermorelin's historical FDA approval means some insurance plans and clinics can prescribe it more readily than CJC-1295.

This is where the two compounds diverge most sharply.

Sermorelin was FDA-approved in 1997 under the brand name Geref Diagnostic (for GH deficiency diagnosis) and as Geref for treatment of pediatric GH deficiency. EMD Serono, the manufacturer, voluntarily discontinued Geref due to manufacturing challenges, not safety signals. Sermorelin has a documented FDA safety review on record. Compounding pharmacies can legally produce sermorelin as a compounded medication with a valid prescription.

CJC-1295 was developed by ConjuChem Biotechnologies (now dissolved) and progressed through Phase I/II trials but was never submitted for FDA approval. It is classified as a research compound. Compounding pharmacies produce it under the 503B framework, but its regulatory status is less established than sermorelin's.

The 2024 FDA PCAC (Pharmacy Compounding Advisory Committee) meetings addressed compounded peptides broadly. Both sermorelin and CJC-1295 remain available through licensed compounding pharmacies, but regulatory changes could affect access. Users who value regulatory certainty may prefer sermorelin. For a perspective on whether sermorelin is a steroid, see our explainer.

Your primary goal determines the better option. The following framework accounts for goals, risk tolerance, and practical preferences.

Stacking CJC-1295 and sermorelin together is not standard practice. Both compounds target the same receptor (the GHRH receptor on pituitary somatotrophs). Using two GHRH agonists simultaneously creates redundancy, not synergy. The receptor can only respond so many times per hour, regardless of how many agonists are competing for it.

The productive stacks pair a GHRH analog with a GHRP (growth hormone-releasing peptide). These two classes activate different receptors that work synergistically.

For a broader look at which GH peptides compare, see our tesamorelin vs CJC-1295 and three-way GH peptide comparison. For stacking strategy, see our peptide stacking guide.